07:22:59 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Qlife Holding är verksamma inom medicinteknik. Bolaget är specialiserade inom forskning och utveckling av IVD-enheter. Enheterna används som biomarkörstester i blod och används som komplement till övriga tester inom vården. Samarbete utförs även med övriga aktörer på marknaden. Störst verksamhet återfinns inom den nordiska marknaden, med huvudkontoret i Helsingborg.

Kalender

2022-02-17 Bokslutskommuniké 2021
2021-11-08 Kvartalsrapport 2021-Q3
2021-08-16 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning QLIFE 0.00 SEK
2021-05-05 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-18 Bokslutskommuniké 2020
2020-11-19 Extra Bolagsstämma 2020
2020-11-18 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-22 Ordinarie utdelning QLIFE 0.00 SEK
2020-05-20 Årsstämma 2020
2020-05-20 Kvartalsrapport 2020-Q1
2021-01-29 08:00:00

Qlife announces today that Denmark's infectious disease agency, Statens Serum Institut, has placed an order of 50 Egoo.Health devices and associated SARS-CoV-2 test capsules. The order represents a value of approximately 1 MDKK, and Qlife expects to complete the delivery in February 2021.

"It is of great importance for Qlife to get a significant order from a highly professional customer directly after the CE-marking. It manifests the demand for tests of laboratory quality combined with fast results, which is exactly what the Egoo test delivers. The Egoo.Health platform is optimal for usage in locations with limited access to central lab facilities, it is easy to use and delivers test results immediately electronically. We are proud to initiate the commercialization journey of the Egoo.health platform, as it will be a unique tool in the current fight against the pandemic", says Jakob Broberg Lind, Director of Sales at Qlife.

The test can provide rapid detection of the current pandemic coronavirus SARS-CoV-2 in 30 minutes with less than a minute of hands on time to prepare the sample.

Egoo's SARS-CoV-2 can be utilized in multiple settings where actionable test results are needed to make informed treatment decisions quickly. The test delivers near-patient results with the same level of performance seen in reference labs.